will knowledge of the molecular pathology of lymphoma improve clinical trials?
Published 4 years ago • 97 plays • Length 11:43Download video MP4
Download video MP3
Similar videos
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
6:23
molecular classification, biology-based clinical trials and liquid biopsy in lymphoma
-
1:21
the future of lymphoma treatment – combining new therapies with molecular diagnosis
-
1:48
novel immunotherapy approaches in lymphoma: car-t cells, bispecifics & sequencing
-
2:03
novel therapeutic agents in the treatment of hodgkin and non-hodgkin lymphoma
-
1:06
molecules versus cells for hodgkin lymphoma management
-
1:19:17
an insider's look: innovations in malignant hematology research
-
2:14
small molecule therapies | moa animation
-
46:33
understanding biomarker testing
-
0:50
update on the pimms trial of ivosidenib for patients with idh1-mutated ccus
-
1:38
using circulating tumor dna in lymphoma: clinical trials & clinical practice
-
2:53
considering the sequencing of covalent and non-covalent btk inhibitors in cll
-
1:21
novel approaches to harnessing the immune system in lymphoma
-
16:57
clinical trials, pathologies and developments in personalized medicine
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:25
the future of car-t for the treatment of lymphoma
-
1:32
promising novel immunotherapeutic approaches in lymphoma
-
6:25
novel tools to monitor the immune system in lymphoma clinical trials
-
1:59
hodgkin lymphoma: prognostic markers in the era of novel treatments
-
1:14
are biomarkers the future in non-hodgkin lymphoma?
-
1:15
biomarkers being explored in hodgkin lymphoma: the role of ctdna